Loading...
•
Dec 31, 2022
Heron Therapeutics Q4 2022 Earnings Report
Reported financial results for Q4 2022 and highlighted recent corporate updates.
Key Takeaways
Heron Therapeutics reported a net product sales increase for the fourth quarter of 2022, driven by growth in both its acute care and oncology care franchises. The company launched APONVIE and saw continued growth in ZYNRELEF sales. A significant reduction in cost of goods for CINVANTI was achieved.
ZYNRELEF net product sales increased 44% over the prior quarter to $3.9 million.
Oncology care franchise net product sales were $26.1 million, compared to $19.9 million for the same period in 2021.
CINVANTI net product sales were $23.1 million, compared to $17.4 million for the same period in 2021.
SUSTOL net product sales were $3.0 million, compared to $2.5 million for the same period in 2021.
Heron Therapeutics
Heron Therapeutics
Heron Therapeutics Revenue by Segment
Revenue by Segment
CINVANTI Revenue
CapyFin.comSUSTOL Revenue
CapyFin.comZYNRELEF Revenue
CapyFin.com Forward Guidance
Heron currently expects full-year 2023 net product sales for the oncology care franchise of $99 million to $103 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income